



## **ArmaGen to Present at Upcoming Investor Conferences**

Calabasas, Calif., February 27, 2017 – ArmaGen, Inc. a privately held biotechnology company focused on developing groundbreaking therapies to treat severe neurological disorders, today announced that ArmaGen’s chief executive officer, Mathias Schmidt, Ph.D., will present at the following investor conferences in March and April.

- ***Cowen and Company 37th Annual Health Care Conference***
  - **When:** Monday, March 6, 2017 at 9:00am ET
  - **Where:** The Boston Marriott Copley Place in Boston
- ***BioCentury 24th Annual Future Leaders in the Biotech Industry investment conference***
  - **When:** Friday, April 7, 2017 at 8:30am ET
  - **Where:** The Millennium Broadway Hotel & Conference Center in New York City

### **About ArmaGen**

ArmaGen, Inc., is a privately held biotechnology company focused on developing groundbreaking therapies for severe neurological disorders. The company is developing a robust pipeline of innovative therapies for the treatment of lysosomal storage disorders including neurological symptoms such as Hurler syndrome (MPS I), Hunter syndrome (MPS II), metachromatic leukodystrophy, Sanfilippo A and B syndromes, as well as other diseases with severe central nervous system manifestations. ArmaGen’s pipeline is based on decades of scientific leadership in engineering therapies to cross the blood-brain barrier and a dominant intellectual property portfolio. The company is advancing its pipeline through licensing and collaboration agreements, in-house development programs, and other partnering opportunities. For more information, visit [www.armagen.com](http://www.armagen.com).

###

### **Investor Contact:**

ArmaGen, Inc.  
Derek Kelaita  
Vice President, Business Development  
818-252-8200  
[dkelaita@armagen.com](mailto:dkelaita@armagen.com)

### **Media Contact:**

SmithSolve  
Alex Van Rees  
973-442-1555 ext. 111  
[alex.vanrees@smithsolve.com](mailto:alex.vanrees@smithsolve.com)